Prolia ® (denosumab) is a specialized injectable treatment for women experiencing osteoporosis. Women who are candidates of Prolia use have post-menopausal osteoporosis and are at high risk for fracture. Prolia is proven to help protect bones by increasing bone density. This makes bones stronger and less resilient to a stress fracture or break. Through clinical trials, Prolia was proven to significantly reduce fractures of the spine, hip, and other bones. Prolia is given as a shot twotimes a year. Patients who receive Prolia treatment should take calcium andvitamin D as recommended by their doctor. Prolia can have adverse side effects so it is important to ask questions as to how it may affect your heath.
Bone remodeling is the process by which the body continuously removes old bone tissue and replaces it with new bone. It is driven by various types of cells, most notably osteoblasts (which secrete new bone) and osteoclasts (which break down bone).
Prolia inhibits this maturation of osteoclasts by binding to and inhibiting the protein that signals bone removal. This protects bone from degradation, and helps to counter the progression of the disease. It serves as a fully human monoclonal antibody for the treatment of osteoporosis, treatment-induced bone loss, bone metastases, rheumatoid arthritis, multiple myeloma, and giant cell tumor of bone.
Prolia is designed to target a protein that acts as the primary signal for bone removal. In many bone loss conditions, this protein overwhelms the body’s natural defenses against bone destruction. In June 2010, denosumab was approved by the U.S. Food and Drug Administration (FDA) for use in postmenopausal women with risk of osteoporosis under the trade name Prolia and in November 2010, as Xgeva, for the prevention of skeleton-related events in patients with bone metastases from solid tumors.